Cargando…

Classification of advanced stages of Parkinson’s disease: translation into stratified treatments

Advanced stages of Parkinson’s disease (advPD) still impose a challenge in terms of classification and related stage-adapted treatment recommendations. Previous concepts that define advPD by certain milestones of motor disability apparently fall short in addressing the increasingly recognized comple...

Descripción completa

Detalles Bibliográficos
Autores principales:	Krüger, Rejko, Klucken, Jochen, Weiss, Daniel, Tönges, Lars, Kolber, Pierre, Unterecker, Stefan, Lorrain, Michael, Baas, Horst, Müller, Thomas, Riederer, Peter
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Vienna 2017
Materias:	Neurology and Preclinical Neurological Studies - Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514193/ https://www.ncbi.nlm.nih.gov/pubmed/28342083 http://dx.doi.org/10.1007/s00702-017-1707-x

Ejemplares similares

Blood-based biomarker in Parkinson’s disease: potential for future applications in clinical research and practice
por: Tönges, Lars, et al.
Publicado: (2022)

Missing heritability in Parkinson’s disease: the emerging role of non-coding genetic variation
por: Ohnmacht, Jochen, et al.
Publicado: (2020)

Data-driven subtyping of Parkinson’s disease: comparison of current methodologies and application to the Bochum PNS cohort
por: Chen, Qiang, et al.
Publicado: (2023)

The Emerging Role of RHOT1/Miro1 in the Pathogenesis of Parkinson's Disease
por: Grossmann, Dajana, et al.
Publicado: (2020)

Bidirectional Relation Between Parkinson's Disease and Glioblastoma Multiforme
por: Mencke, Pauline, et al.
Publicado: (2020)

Significance of clinical symptoms and red flags in early differential diagnosis of Parkinson’s disease and atypical Parkinsonian syndromes
por: Schröter, Nils, et al.
Publicado: (2023)

Multilingual Validation of the First French Version of Munich Dysphagia Test—Parkinson's Disease (MDT-PD) in the Luxembourg Parkinson's Study
por: Simons, Janine A., et al.
Publicado: (2019)

Implications of dopaminergic medication withdrawal in Parkinson’s disease
por: Koschel, J., et al.
Publicado: (2021)

The Diagnostic Scope of Sensor-Based Gait Analysis in Atypical Parkinsonism: Further Observations
por: Gaßner, Heiko, et al.
Publicado: (2019)

L-DOPA-therapy in Parkinson’s disease: some personal reflections on L-DOPA therapy from Vienna and Berlin
por: Riederer, Peter, et al.
Publicado: (2023)

The heterogeneity of Parkinson’s disease
por: Wüllner, Ullrich, et al.
Publicado: (2023)

Iron as the concert master in the pathogenic orchestra playing in sporadic Parkinson’s disease
por: Riederer, P., et al.
Publicado: (2021)

Editorial: Celebrating the Diversity of Genetic Research to Dissect the Pathogenesis of Parkinson's Disease
por: Farrer, Matthew J., et al.
Publicado: (2021)

Brainstem Raphe Alterations in TCS: A Biomarker for Depression and Apathy in Parkinson's Disease Patients
por: Richter, Daniel, et al.
Publicado: (2018)

Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson’s disease
por: Riederer, Peter, et al.
Publicado: (2023)

Shared cerebral metabolic pathology in non-transgenic animal models of Alzheimer's and Parkinson's disease
por: Barilar, Jelena Osmanovic, et al.
Publicado: (2020)

Plasma autoantibodies to glial fibrillary acidic protein (GFAP) react with brain areas according to Braak staging of Parkinson’s disease
por: Gschmack, Eva, et al.
Publicado: (2022)

Unmet Needs of People With Parkinson's Disease and Their Caregivers During COVID-19-Related Confinement: An Explorative Secondary Data Analysis
por: Hanff, Anne-Marie, et al.
Publicado: (2021)

Exploration of whether socioeconomic factors affect the results of priority setting partnerships: updating the top 10 research priorities for the management of Parkinson’s in an international setting
por: Bowring, Francesca, et al.
Publicado: (2022)

GBA-associated PD: chances and obstacles for targeted treatment strategies
por: Höglinger, Günter, et al.
Publicado: (2022)

Contributing Factors and Evolution of Impulse Control Disorder in the Luxembourg Parkinson Cohort
por: Binck, Sylvia, et al.
Publicado: (2020)

The role of tyrosine hydroxylase as a key player in neuromelanin synthesis and the association of neuromelanin with Parkinson’s disease
por: Nagatsu, Toshiharu, et al.
Publicado: (2023)

Leveraging the Potential of Digital Technology for Better Individualized Treatment of Parkinson's Disease
por: Fröhlich, Holger, et al.
Publicado: (2022)

Corrigendum: Contributing Factors and Evolution of Impulse Control Disorder in the Luxembourg Parkinson Cohort
por: Binck, Sylvia, et al.
Publicado: (2021)

Age-Stratified Risk of Dementia in Parkinson's Disease: A Nationwide, Population-Based, Retrospective Cohort Study in Taiwan
por: Chang, Ting-Ya, et al.
Publicado: (2021)

Long-Term Effect of GPi-DBS in a Patient With Generalized Dystonia Due to GLUT1 Deficiency Syndrome
por: Hanci, Idil, et al.
Publicado: (2018)

Treatment of Parkinson’s disease in the advanced stage
por: Ossig, C., et al.
Publicado: (2013)

Drug safety profiles in geriatric patients with Parkinson’s disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis
por: Greten, S., et al.
Publicado: (2020)

Genetic Architecture of Parkinson's Disease in the Indian Population: Harnessing Genetic Diversity to Address Critical Gaps in Parkinson's Disease Research
por: Rajan, Roopa, et al.
Publicado: (2020)

Coronaviruses: a challenge of today and a call for extended human postmortem brain analyses
por: Riederer, Peter, et al.
Publicado: (2020)

Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?
por: Heinzel, Sebastian, et al.
Publicado: (2018)

Levodopa improves handwriting and instrumental tasks in previously treated patients with Parkinson’s disease
por: Müller, Thomas, et al.
Publicado: (2020)

Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson’s disease
por: Jenner, P., et al.
Publicado: (2023)

Amantadine: reappraisal of the timeless diamond—target updates and novel therapeutic potentials
por: Danysz, Wojciech, et al.
Publicado: (2021)

Viruses, parkinsonism and Parkinson’s disease: the past, present and future
por: Leta, Valentina, et al.
Publicado: (2022)

Access to device-aided therapies in advanced Parkinson’s disease: navigating clinician biases, patient preference, and prognostic uncertainty
por: Auffret, Manon, et al.
Publicado: (2023)

Comparison of Three Motor Subtype Classifications in de novo Parkinson's Disease Patients
por: Ren, Jingru, et al.
Publicado: (2020)

Selegiline: a molecule with innovative potential
por: Tábi, Tamás, et al.
Publicado: (2019)

Clinical Outcome in Patients With Intracerebral Hemorrhage Stratified by Type of Antithrombotic Therapy
por: Baharoglu, Merih Irem, et al.
Publicado: (2021)

The Greek Version of Mini-Manual Ability Classification System (Mini-MACS): Translation and Reliability Study
por: Skoutelis, Vasileios C, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ai3tof9sa4obfeujhdr59g5cej